All In Biotech

BLA 761204 · Amicus Therap US

Pombiliti

Cipaglucosidase Alfa-Atga · Injection

NovelBreakthrough therapyOrphan

CDER novel approval, Sep 28, 2023: To treat late-onset Pompe disease

Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 28, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

4 Phase 3, 2 recruiting

FAERS reports

91

47 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS Hypersensitivity Reactions Including Anaphylaxis Patients treated with POMBILITI have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during POMBILITI administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, POMBILITI should be discontinued immediately, and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, desensitization measures to POMBILITI may be considered [see Warnings and Precautions (5.1) ]. Infusion-Associated Reactions (IARs) Patients treated with POMBILITI have experienced severe IARs. If severe IARs occur,...

What it is approved for

From the label in effect Aug 12, 2026.

POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). POMBILITI is a hydrolytic lysosomal glycogen-specific enzyme indicated, in combination with Opfolda, an enzyme stabilizer, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). ( 1 )

Mechanism: Pompe disease (also known as glycogen storage disease type II, acid maltase deficiency, and glycogenosis type II) is an inherited disorder of glycogen metabolism caused by a deficiency of lysosomal acid alpha‑glucosidase (GAA) that degrades glycogen to glucose in the lysosome. GAA deficiency results in intra-lysosomal accumulation of glycogen in various tissues. Cipaglucosidase alfa-atga provides an exogenous source of GAA. The bis-M6P on cipaglucosidase alfa-atga mediates binding to M6P receptors on the cell surface with high affinity. After binding, it is internalized and transported into...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 28, 2023 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • POMBILITI · CIPAGLUCOSIDASE ALFA-ATGA 105MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cipaglucosidase Alfa" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue10
  • nausea10
  • asthenia7
  • product dose omission issue7
  • vomiting7
  • malaise6
  • death5
  • dyspnoea5
  • headache5
  • hypertension5
  • infusion related reaction5
  • pneumonia5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202428
202530
202633

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pombiliti (Cipaglucosidase Alfa-Atga)

2024 spending

$5.8M

Beneficiaries

13

107 claims

Per beneficiary

$445,836

$1,818.60 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$5,795,874

Part B: Pombiliti (Cipaglucosidase Alfa-Atga) · HCPCS J1203

2024 spending

$2.7M

Beneficiaries

13

87 claims

Per beneficiary

$207,185

2024 ASP limit $88.10 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$2,693,409

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: Amicus Therap US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.